Neuroprotective versus tumorigenic protein kinase C activators.


Protein kinase C (PKC) activators possess potent neurotrophic and neuroprotective activity, thus indicating potential applications in treating neurodegenerative diseases, stroke and traumatic brain injury. Although some activators, such as bryostatin and gnidimacrin, have been tested as antitumor agents, others, such as phorbol esters, are potent tumor… (More)
DOI: 10.1016/j.tibs.2008.11.006


Cite this paper

@article{Nelson2009NeuroprotectiveVT, title={Neuroprotective versus tumorigenic protein kinase C activators.}, author={T. J. Nelson and Daniel L. Alkon}, journal={Trends in biochemical sciences}, year={2009}, volume={34 3}, pages={136-45} }